Encoded Therapeutics Inc. ("Encoded"), a clinical-stage biotechnology company developing precision genetic medicines for severe neurological disorders, today will present new preclinical data across ...
ETX101 reduced seizures and improved neurodevelopmental outcomes, but its impact was unexpectedly attenuated by using the immunosuppressive drug.
New POLARIS Phase I/II data presented at ASGCT show ETX101 gene therapy reducing seizures and improving neurodevelopment in children with SCN1A+ Dravet syndrome.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results